Aquestive Therapeutics Reports Positive Initial Topline

AQST-109 is the first and only orally delivered epinephrine product candidate in clinical developmentFastest median time to maximum concentration (Tmax) in...

Related Keywords

Canada ,United States ,Medstar Franklin Square ,Dan Barber ,Linkedin ,Allergy Division ,Drug Administration ,Health Canada ,Nasdaq ,Aquestive Therapeutics Inc ,Area Under ,Mean Cmax ,Proof Of Concept Study ,Chief Executive Officer ,David Golden ,Medstar Franklin Square Hospital ,Pre Investigational New Drug Application ,Fast Track ,Nasdaq Aqst ,Aquestive Therapeutics ,Nc ,